A Rapid Shift in Treatment for Chronic Lymphocytic Leukemia - Episode 10

Progression on Frontline Ibrutinib in CLL

EP. 1: Risk Assessment in Newly Diagnosed CLL
EP. 2: Up-front Ibrutinib Versus FCR for Patients With CLL
EP. 3: Frontline Antibodies With BTK Inhibitors for CLL
EP. 4: Toxicities With BTK Inhibitors for CLL
EP. 5: Comparison of BTK Inhibitors for CLL
EP. 6: Obinutuzumab + Venetoclax for Frontline CLL
EP. 7: MRD Testing for CLL
EP. 8: Ibrutinib + Venetoclax for Frontline CLL
EP. 9: Resistance Mechanisms Associated With BTK Inhibitors
Now Viewing
EP. 10: Progression on Frontline Ibrutinib in CLL
EP. 11: Venetoclax in R/R CLL
EP. 12: BTK Inhibitors in R/R CLL
EP. 13: PI3K Inhibitors in R/R CLL
EP. 14: Novel Combinations in Development for CLL
EP. 15: Final Thoughts From ASH 2019 in CLL

Transcript:

Related Content:

A Rapid Shift in Treatment for Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaHematologic OncologyOncology Nursing NewsSupportive Care
FDA Grants Fast Track Status to Eryaspase for Hypersensitive Acute Lymphocytic Leukemia
Zanubrutinib Significantly Prolongs PFS Over Chemoimmunotherapy in Treatment-Naïve CLL
Frontline Therapy for Patients With CLL: Testing and Risk Classification